Recent 8-K filings for ELDN
Highest-materiality recent filing
Eledon Pharmaceuticals Restates Prior Financials and Reports Q2 2025 Results
- Restated financial statements for fiscal years 2023 and 2024 and Q1 2025 due to misclassification of Series X and X1 preferred stock; will reclassify as temporary equity.
- Identified a material weakness in internal control over financial reporting related to accounting for equity instruments; controls and disclosure controls were not effective.
-
Eledon Q1 net loss $39M; cash $111.1M; 100% insulin independence in islet trial
Cash, equivalents and short-term investments $111.1M as of March 31, 2026, down from $133.3M at Dec 31, 2025; funding expected into Q2 2027.
-
Eledon FY2025 net loss $45.6M; tegoprubart data shows insulin independence in T1D islet transplant
Net loss for FY2025 was $45.6M ($0.52/share) vs $36.2M loss in FY2024; non-GAAP net loss (excl warrant gain) was $79.1M.
-
Eledon reports Q3 net loss $17.5M; Phase 2 BESTOW positive; raises $57.5M
Net loss $17.5M ($0.21/shr) vs net income $77M (incl $96.4M warrant gain) in Q3 2024.
-
Eledon raises ~$46.5M in public offering of common stock and pre-funded warrants
Underwritten offering of 15.15M shares at $1.65/share and up to 15.15M pre-funded warrants at $1.649/warrant.
-
Primary efficacy endpoint (eGFR at 12 months) did not reach statistical significance: 69 vs 66 mL/min/1.73 m².
-
Eledon Pharmaceuticals Restates Prior Financials and Reports Q2 2025 Results
Restated financial statements for fiscal years 2023 and 2024 and Q1 2025 due to misclassification of Series X and X1 preferred stock; will reclassify as temporary equity.
-
On-treatment patients (n=12) showed mean eGFR ~68 mL/min/1.73m² at 12 months; ITT population (n=15) ~63 mL/min/1.73m².
-
Eledon Q1 net loss $6.5M; cash $124.9M; on track for BESTOW topline in Q4
Net loss of $6.5M ($0.08/share) vs $23.6M loss in Q1 2024; adjusted net loss $16.6M vs $10.3M.
-
Eledon Q4 net loss $44.6M; cash runway extended; tegoprubart used in pig kidney transplant
Q4 2024 net loss $44.6M ($0.64/shr) vs $30.1M ($1.00/shr) in Q4 2023; includes non-cash warrant loss $20.9M.
-
Eledon completes BESTOW enrollment early; reports $77M net income on non-cash gain
Phase 2 BESTOW trial for tegoprubart in kidney transplant hit target of 120 patients ~4 months ahead of schedule.
-
Eledon Pharmaceuticals prices $85M offering of common stock and pre-funded warrants at $3.65/share
Gross proceeds ~$85M; net proceeds ~$79.5M after underwriting discounts and expenses.
-
Eledon's tegoprubart enables insulin independence in first two islet transplant recipients with T1D
First two subjects achieved insulin independence post-transplant; third subject on trajectory with >60% insulin reduction at day 3.
-
Non-reliance on FY2023 and Q1 2024 financials due to warrant derivative accounting error; expects restatement and amendments.
-
Eledon Q1 net loss $10.3M ($0.34/share); cash $42.9M; $50M private placement
Net loss of $10.3M ($0.34 diluted EPS) vs $10.8M loss ($0.75 EPS) in Q1 2023.
-
Eledon raises $50M in oversubscribed private placement; tegoprubart advances in transplant trials
Gross proceeds ~$50M from 13.1M shares at $2.37/sh and 7.99M pre-funded warrants at $0.001/sh.
-
Eledon posts Q4 net loss $9.6M, highlights Phase 2 BESTOW enrollment and xenotransplant use
Net loss of $9.6M ($0.32/shr) for Q4 2023; full year net loss $40.3M ($1.64/shr).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.68 · Most common event other_material